Can-Fite BioPharma Ltd. Statistics
Share Statistics
Can-Fite BioPharma Ltd. has 1.83B shares outstanding. The number of shares has increased by 36548.7% in one year.
| Shares Outstanding | 1.83B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 26790.53% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.67B |
| Failed to Deliver (FTD) Shares | 54.31K |
| FTD / Avg. Volume | 11.9% |
Short Selling Information
The latest short interest is 361.09K, so 0.02% of the outstanding shares have been sold short.
| Short Interest | 361.09K |
| Short % of Shares Out | 0.02% |
| Short % of Float | 0.02% |
| Short Ratio (days to cover) | 0.35 |
Valuation Ratios
The PE ratio is -1.24 and the forward PE ratio is -2.85.
| PE Ratio | -1.24 |
| Forward PE | -2.85 |
| PS Ratio | 12.78 |
| Forward PS | 0.3 |
| PB Ratio | 1.52 |
| P/FCF Ratio | -1.13 |
| PEG Ratio | n/a |
Enterprise Valuation
Can-Fite BioPharma Ltd. has an Enterprise Value (EV) of 9.41M.
| EV / Earnings | -1.23 |
| EV / Sales | 12.67 |
| EV / EBITDA | -1.15 |
| EV / EBIT | -1.15 |
| EV / FCF | -1.12 |
Financial Position
The company has a current ratio of 4.9, with a Debt / Equity ratio of 0.
| Current Ratio | 4.9 |
| Quick Ratio | 4.9 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -585.36 |
Financial Efficiency
Return on equity (ROE) is -1.22% and return on capital (ROIC) is -130.43%.
| Return on Equity (ROE) | -1.22% |
| Return on Assets (ROA) | -0.76% |
| Return on Capital (ROIC) | -130.43% |
| Revenue Per Employee | 92.88K |
| Profits Per Employee | -954.25K |
| Employee Count | 8 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -20.1% in the last 52 weeks. The beta is 0.57, so Can-Fite BioPharma Ltd.'s price volatility has been higher than the market average.
| Beta | 0.57 |
| 52-Week Price Change | -20.1% |
| 50-Day Moving Average | 1.8 |
| 200-Day Moving Average | 2.33 |
| Relative Strength Index (RSI) | 47.2 |
| Average Volume (20 Days) | 456.27K |
Income Statement
In the last 12 months, Can-Fite BioPharma Ltd. had revenue of 743.00K and earned -7.63M in profits. Earnings per share was -1.79.
| Revenue | 743.00K |
| Gross Profit | 743.00K |
| Operating Income | -8.20M |
| Net Income | -7.63M |
| EBITDA | -8.18M |
| EBIT | -8.20M |
| Earnings Per Share (EPS) | -1.79 |
Balance Sheet
The company has 4.28M in cash and 40.00K in debt, giving a net cash position of 4.24M.
| Cash & Cash Equivalents | 4.28M |
| Total Debt | 40.00K |
| Net Cash | 4.24M |
| Retained Earnings | -158.48M |
| Total Assets | 5.92M |
| Working Capital | 3.84M |
Cash Flow
In the last 12 months, operating cash flow was -8.44M and capital expenditures -2.00K, giving a free cash flow of -8.44M.
| Operating Cash Flow | -8.44M |
| Capital Expenditures | -2.00K |
| Free Cash Flow | -8.44M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 100%, with operating and profit margins of -1.10K% and -1.03K%.
| Gross Margin | 100% |
| Operating Margin | -1.10K% |
| Pretax Margin | -1.03K% |
| Profit Margin | -1.03K% |
| EBITDA Margin | -1.10K% |
| EBIT Margin | -1.10K% |
| FCF Margin | -1.14K% |
Dividends & Yields
CANF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -112.58% |
| FCF Yield | -87.09% |
Analyst Forecast
The average price target for CANF is $10, which is 528.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 528.9% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jan 9, 2023. It was a forward split with a ratio of 10:1.
| Last Split Date | Jan 9, 2023 |
| Split Type | forward |
| Split Ratio | 10:1 |
Scores
| Altman Z-Score | -39.98 |
| Piotroski F-Score | 2 |